Terms of Use

As of July 8, 2025

The website located at www.bambusatx.com, including its subdomains (“Website”), is a copyrighted work belonging to Bambusa Therapeutics, Inc. and/or its subsidiaries (“Bambusa”, “us”, “our”, and “we”). Certain features of the Website may be subject to additional guidelines, terms, or rules, which will be posted on the Website in connection with such features. All such additional terms, guidelines, and rules are incorporated by reference into these Terms. In addition, please read our Privacy Policy for important information about how we collect, use, disclose, and otherwise process your personal information.

THIS TERMS OF USE AGREEMENT (THESE “TERMS”) SET FORTH THE LEGALLY BINDING TERMS AND CONDITIONS THAT GOVERN YOUR USE OF THE WEBSITE. BY ACCESSING OR USING THE WEBSITE, YOU ARE ACCEPTING THESE TERMS (ON BEHALF OF YOURSELF OR THE ENTITY THAT YOU REPRESENT), AND YOU REPRESENT AND WARRANT THAT YOU HAVE THE RIGHT, AUTHORITY, AND CAPACITY TO ENTER INTO THESE TERMS (ON BEHALF OF YOURSELF OR THE ENTITY THAT YOU REPRESENT). THESE TERMS CONTAIN (A) VARIOUS LIMITATIONS, EXCLUSIONS AND RELEASES OF LIABILITY IN SECTIONS 3, 6 AND 9.5 AND (B) A WAIVER OF RIGHTS TO PARTICIPATE IN A JURY TRIAL REGARDING ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF THESE TERMS OR YOUR USE OF THE WEBSITE IN SECTION 9.6.

YOU MAY NOT ACCESS OR USE THE WEBSITE OR ACCEPT THE TERMS IF YOU ARE NOT AT LEAST 18 YEARS OLD. IF YOU DO NOT AGREE WITH ALL OF THE PROVISIONS OF THESE TERMS, DO NOT ACCESS AND/OR USE THE WEBSITE.

1. General

1.1. Bambusa owns, controls, and maintains this Website for your information and education and as a service to the internet community. Any information contained or referenced in this Website is suitable only as an introduction to Bambusa. This Website may contain third party information. Such information is, wherever reasonably possible, marked with the name of the source. Such third-party information does not necessarily represent our views, and we take no responsibility whatsoever for such third-party information, nor do we adopt or endorse any such information.

1.2. We reserve the right to change (in whole or in part) these Terms from time to time at our sole discretion. If we make changes to these Terms, we will notify you by posting notice of the changes on our Website. If you have given us your email address, we also may notify you by email. Any changes to these Terms will be effective upon thirty (30) calendar days following our posting of notice of the changes on our Website. These changes will be effective immediately for new users of our Website. Continued use of our Website following notice of such changes shall indicate your acknowledgement of such changes and agreement to be bound by the terms and conditions of such changes. If you do not agree with any updated version of these Terms, do not continue to use our Website.

2. Limited License to Access Website

2.1 License. All contents on our Website are, to the extent possible, protected by copyright or otherwise proprietary. Subject to these Terms, we grant you a non-transferable, non-exclusive, revocable, limited license to access, view and copy materials on the public portions of our Website solely for non-commercial, personal, and informational use. No other use of the information is authorized. Nothing contained in these Terms shall be construed as conferring by implication, estoppel, or otherwise, any license or right under any patent, trademark, or copyright of any third party (including without limitation any of our licensors) or ours.

2.2 Certain Restrictions. The rights granted to you in these Terms are subject to the following restrictions: (a) you shall not license, sell, rent, lease, transfer, assign, distribute, host, or otherwise commercially exploit the Website, whether in whole or in part, or any content displayed on the Website; (b) you shall not modify, make derivative works of, disassemble, reverse compile or reverse engineer any part of the Website; (c) you shall not access the Website in order to build a similar or competitive website, product, or service; and (d) except as expressly stated in these Terms, no part of the Website may be copied, reproduced, distributed, republished, downloaded, displayed, posted or transmitted in any form or by any means. Unless otherwise indicated, any future release, update, or other addition to functionality of the Website shall be subject to these Terms. All copyright and other proprietary notices on the Website (or on any content displayed on the Website) must be retained on all copies. You will not remove, alter, or obscure any copyright, trademark, service mark or other proprietary rights notices incorporated in or accompanying any Bambusa materials or content.

2.3 Modification. We reserve the right, at any time, to modify, suspend, or discontinue the Website (in whole or in part) with or without notice to you. You agree that we will not be liable to you or to any third party for any modification, suspension, or discontinuation of the Website or any part of it.

2.4 No Support or Maintenance. You acknowledge and agree that we will have no obligation to provide you with any support or maintenance in connection with the Website.

2.5 Ownership. You acknowledge that all the intellectual property rights, including copyrights, patents, trademarks, and trade secrets, on the Website and its content are owned by us or our licensors. Neither these Terms nor your access to the Website transfers to you or any third party any rights, title, or interest in or to such intellectual property rights, except for the limited access rights expressly set forth in Section 2.1. You are not permitted to use the trademarks, tradenames, service marks, trade dress, or logos appearing on this Website (the “Marks”) without our prior written consent and, if applicable, the consent of the third-party that owns the Marks.

2.6 Acceptable Use Policy. You agree not to: (a) upload, transmit, or distribute to or through the Website any computer viruses, any worms, or any software intended to damage or alter a computer system or data; (b) send through the Website any unsolicited or unauthorized advertising, promotional materials, junk mail, or spam, or any harassing or abusive material or any other unlawful material; (c) interfere with, disrupt, or create an undue burden on servers or networks connected to the Website, or violate the regulations, policies or procedures of such networks; (d) violate the security of the Website or attempt to gain unauthorized access to the Website (or to other computer systems or networks connected to or used together with the Website), whether through password mining or any other means; (e) use software or automated agents or scripts to generate automated searches, requests, or queries to (or to strip, scrape, or mine data from) the Website (provided, however, that we conditionally grant to the operators of public search engines revocable permission to use spiders to copy materials from the Website for the sole purpose of and solely to the extent necessary for creating publicly available searchable indices of the materials, but not caches or archives of such materials, subject to the parameters set forth in our robots.txt file); or (f) use the Website in any way that violates any applicable federal, state, local or international statute, regulation rule, order, treaty or other law.

2.7 Enforcement. We reserve the right (but have no obligation) to investigate and/or take appropriate action against you in our sole discretion if you violate any provision of these Terms or otherwise create liability for us or any other person. In the case of any violation of these Terms, we reserve the right to seek all remedies available by law and in equity for such violations. Such action may include reporting you to law enforcement authorities or terminating your license to access and use the Website without prior notice to you.

3. Disclaimers

3.1 THE WEBSITE AND THE CONTENT PROVIDED ON THE WEBSITE RELATING TO OUR TECHNOLOGY AND OUR PRODUCTS IS PROVIDED ON AN “AS-IS” AND “AS AVAILABLE” BASIS, AND WE AND OUR LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, INCLUDING THOSE OF NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN ADDITION, WE SHALL NOT BE LIABLE IN ANY WAY FOR POSSIBLE ERRORS OR OMISSIONS IN THE CONTENT OF OUR WEBSITE. ALTHOUGH WE HAVE ATTEMPTED TO PROVIDE ACCURATE INFORMATION ON OUR WEBSITE, WE ASSUME NO RESPONSIBILITY FOR THE ACCURACY OR RELIABILITY OF THE INFORMATION AND WE AND OUR LICENSORS MAKE NO WARRANTY THAT THE WEBSITE WILL MEET YOUR REQUIREMENTS, WILL BE AVAILABLE ON AN UNINTERRUPTED, TIMELY, SECURE, OR ERROR-FREE BASIS, OR WILL BE FREE OF VIRUSES OR OTHER HARMFUL CODE, COMPLETE, LEGAL, OR SAFE. IF APPLICABLE LAW REQUIRES ANY WARRANTIES WITH RESPECT TO THE WEBSITE, ALL SUCH WARRANTIES ARE LIMITED IN DURATION TO NINETY (90) DAYS FROM THE DATE OF FIRST USE. IN PARTICULAR, WE MAY NOT UPDATE OUR WEBSITE ON A DAILY OR OTHER REGULAR BASIS. AS SUCH, THE INFORMATION AND MATERIALS CONTAINED ON OUR WEBSITE MAY BE OUT OF DATE OR INCLUDE OMISSIONS OR OTHER ERRORS. WE MAY CHANGE THE INFORMATION PROVIDED ON OUR WEBSITE AT ANY TIME WITHOUT NOTICE AND WE WILL NOT BE LIABLE IN ANY WAY FOR POSSIBLE CONSEQUENCES OF SUCH CHANGES.

3.2 SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO THE ABOVE EXCLUSION MAY NOT APPLY TO YOU. SOME JURISDICTIONS DO NOT ALLOW LIMITATIONS ON HOW LONG AN IMPLIED WARRANTY LASTS, SO THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

3.3 This Website is not intended to be used in making any decision relating to an investment in the securities of Bambusa. Investors or prospective investors are urged to review and carefully consider the investment materials that we provide in connection with any offering of securities, and all information contained on this Website is qualified in its entirety by reference to such investment materials, including the risk factors contained in those investment materials. This Website contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern Bambusa’s expectations, strategy, plans, or intentions. Any forward-looking statements on this Website are based on management’s current expectations and beliefs. There are a number of important factors that could cause Bambusa’s actual results to differ materially from those indicated by such forward-looking statements, including those factors described in any filings Bambusa makes with the Securities and Exchange Commission from time to time. Bambusa undertakes no obligation to update any forward-looking statements to reflect new events or circumstances, except as required by law.

3.4 Bambusa is not engaged in rendering medical, healthcare, or other professional advice. This Website may contain information on medical and health-related topics. This information, including any product data, is for informational purposes only and is not intended to describe or make claims about the safety or efficacy of any product. Nothing on the Website (i) is intended to create a physician-patient relationship or (ii) should be construed as the giving of advice or the making of a recommendation regarding any decision or action related to your health or the health of others. Inclusion of content on the Website does not mean that Bambusa supports or recommends a specific treatment, drug, physician, or test in any particular case. The information on this Website is not meant to be a substitute for the advice provided by your own physician or other medical professional, and you should not use this information for diagnosing or treating a health problem or disease. You should always consult your own physician before undertaking or changing any medical treatment, drug therapy, or healthcare activities.

4. Feedback

If you provide us with any feedback or suggestions regarding the Website, any of our products or services, or any other aspect of our business (“Feedback”), you hereby assign to Bambusa all rights in such Feedback and agree that we shall have the right to use and fully exploit such Feedback and related information in any manner we deem appropriate. Any Feedback you transmit to our Website by electronic mail or otherwise, is and will be treated as non-confidential and non-proprietary to you. Unless specifically agreed to by us in writing, we shall have no obligation of any kind with respect to Feedback, and shall be free to use any ideas, concepts, know-how, or techniques contained in any Feedback for any purpose whatsoever, and to reproduce, use, disclose, and distribute such Feedback to third parties without limitation. You agree that you will not submit via our Website any information or ideas that you consider to be confidential or proprietary. You shall be responsible for the content and information contained in submitted Feedback, including its truthfulness and accuracy.

5. Indemnification

You agree to indemnify, defend, and hold harmless Bambusa, its subsidiaries, affiliates, directors, officers, employees, agents and assigns, from and against any and all loss, costs, expenses (including reasonable attorneys’ fees and expenses), claims, damages and liabilities related to, or associated with, (a) your use of this Website; (b) any violation of these Terms by you; or (c) your violation of applicable laws or regulations. We reserve the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify us, and you agree to cooperate with our defense of these claims. You agree not to settle any such matter without our prior written consent. We will use reasonable efforts to notify you of any such claim, action or proceeding upon becoming aware of it.

6. Limitation of Liability

6.1 TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL BAMBUSA OR OUR LICENSORS BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY LOST PROFITS, LOST DATA, COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, OR ANY INDIRECT, CONSEQUENTIAL, EXEMPLARY, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES ARISING FROM OR RELATING TO THESE TERMS OR YOUR USE OF, OR INABILITY TO USE, THE WEBSITE, EVEN IF BAMBUSA HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. ACCESS TO, AND USE OF, THE WEBSITE IS AT YOUR OWN DISCRETION AND RISK, AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR DEVICE OR COMPUTER SYSTEM, OR LOSS OF DATA RESULTING FROM ANY SUCH ACCESS OR USE.

6.2 TO THE MAXIMUM EXTENT PERMITTED BY LAW, NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THESE TERMS, OUR LIABILITY TO YOU FOR ANY DAMAGES ARISING FROM OR RELATED TO THE WEBSITE OR THESE TERMS (FOR ANY CAUSE WHATSOEVER AND REGARDLESS OF THE FORM OF THE ACTION), WILL AT ALL TIMES BE LIMITED TO $100.00 IN THE AGGREGATE. THE EXISTENCE OF MORE THAN ONE CLAIM WILL NOT ENLARGE THIS LIMIT. YOU AGREE THAT OUR LICENSORS WILL HAVE NO LIABILITY OF ANY KIND ARISING FROM OR RELATING TO THESE TERMS.

6.3 SOME JURISDICTIONS DO NOT ALLOW THE LIMITATION OR EXCLUSION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU.

7. Third-Party Links

Our Website may contain hyperlinks to websites owned and/or controlled by other parties (“Third-Party Links”). Access to, or use of, any Third-Party Links is at your own risk, and we are not responsible for the accuracy or reliability of any information accessible from these Third-Party Links. We provide these Third-Party Links merely as a convenience, and the hyperlinks are not an endorsement of, and we do not review, approve, monitor, endorse, warrant, or make any representations with respect to, Third-Party Links. You use all Third-Party Links at your own risk and should apply a suitable level of caution and discretion in doing so. When you click on any of the Third-Party Links, the applicable third-party’s terms and policies apply, including the third-party’s privacy and data gathering practices. You should make whatever investigation you feel necessary or appropriate before proceeding with any transaction in connection with such third-party.

8. Term and Termination

Subject to this Section, these Terms will remain in full force and effect while you use the Website. We may suspend or terminate your right to use the Website at any time for any reason at our sole discretion, including for violation of these Terms. Upon termination of your rights under these Terms, your right to access and use the Website will terminate immediately. We will not have any liability whatsoever to you for any termination of your rights under these Terms. Even after your rights under these Terms are terminated, the following provisions of these Terms will remain in effect: Sections 2.2-2.5, 3 – 6, and 8 – 9.

9. Miscellaneous

9.1 Export. The Website may be subject to U.S. export control laws and may be subject to export or import regulations in other countries. You agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Bambusa, or any products utilizing such data, in violation of the United States export laws or regulations.

9.2 Disclosures. If you are a California resident, you may report complaints to the Complaint Assistance Unit of the Consumer Information Center of the California Department of Consumer Affairs by contacting them in writing at 1625 North Market Blvd., Suite N 112, Sacramento, CA 95834, or by telephone at (800) 952-5210.

9.3 Electronic Communications. When you use the Website or send us emails, you are communicating with us electronically. For contractual purposes, you (a) consent to receive communications from Bambusa in an electronic form; and (b) agree that all terms and conditions, agreements, notices, disclosures, and other communications that Bambusa provides to you electronically satisfy any legal requirement that such communications would satisfy if it were in a hardcopy writing. The above does not affect your non-waivable rights.

9.4 Entire Terms. These Terms constitute the entire agreement between you and us regarding the access and use of the Website. Our failure to exercise or enforce any right or provision of these Terms shall not operate as a waiver of such right or provision. The section titles in these Terms are for convenience only and have no legal or contractual effect. The word “including” means “including without limitation.” If any provision of these Terms is, for any reason, held to be invalid or unenforceable, the other provisions of these Terms will be unimpaired, and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law. Your relationship to Bambusa is that of an independent contractor, and neither party is an agent or partner of the other. These Terms, and your rights and obligations under them, may not be assigned, subcontracted, delegated, or otherwise transferred by you without our prior written consent, and any attempted assignment, subcontract, delegation, or transfer in violation of this paragraph will be null and void. Bambusa may freely assign these Terms. The terms and conditions set forth in these Terms shall be binding upon assignees.

9.5 Release. You hereby release Bambusa and its officers, employees, and agents and their successors from claims, demands, any and all losses, damages, rights, and actions of any kind, including personal injuries, death, and property damage, that is either directly or indirectly related to or arises from your use of the Website, including but not limited to, any interactions with third-party websites of any kind arising in connection with or as a result of your use of the Website. If you are a California resident, you hereby waive California Civil Code Section 1542, which states, “A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.” If you live in a state with any similar law, you hereby waive your rights under that law. This release does not apply to any claims, demands, or any losses, damages, rights, and actions of any kind, including personal injuries, death or property damage for any unconscionable commercial practice by our fraud, deception, false promise, misrepresentation or concealment, suppression or omission of any material fact in connection with the Website.

9.6 Governing Law; Dispute Resolution. These Terms shall be governed by the laws of the Commonwealth of Massachusetts without regard to its rules on conflicts or choice of law. You hereby consent to the exclusive jurisdiction of the courts of Massachusetts for the resolution of any dispute based upon or relating to this Website or these Terms and waive any objection to such courts on any basis, including without limitation venue and inconvenience of the forum. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to use of the Website or these Terms must be filed within one (1) year after such claim or cause of action arose or be forever barred. YOU HEREBY WAIVE YOUR RIGHT TO A JURY TRIAL IN ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF YOUR USE OF THE WEBSITE OR THESE TERMS.

9.7 Compliance with Applicable Laws. We maintain this Website from our offices in Massachusetts. We make no representations that materials in our Website are appropriate or available for use in other locations. For specific information please contact us directly. We make no claims concerning whether the content on this Website may be downloaded, viewed, or be appropriate for use outside of the United States.

9.8 Contact. For any questions about these Terms, please contact:

Bambusa Therapeutics, Inc.
22 Boston Wharf Rd, Floor 7
Boston, MA 02210  

Linkedin-in

Jon Lieber

Chief Financial Officer

Jonathan I. Lieber, MBA, is Chief Financial Officer of Bambusa Therapeutics. Jonathan brings more than 30 years of financial, strategic, and business experience across the life sciences industry.

Jonathan joined Bambusa from Rallybio Corporation, where he has served as Chief Financial Officer since 2023. Previously, he served as Chief Financial Officer of Applied Genetic Technologies Corporation and as a Managing Director at Danforth Advisors, where he provided strategic and operational financial leadership to life sciences companies. Earlier in his career, Jonathan served as Chief Financial Officer of Histogenics Corporation, Metamark Genetics, Repligen Corporation, Xcellerex, and Altus Pharmaceuticals. He began his career in healthcare investment banking at Salomon Brothers/Salomon Smith Barney and Cowen and Company/SG Cowen.

Jonathan currently serves on the boards of directors of Decoy Therapeutics, MindWalk Holdings, and Zola Therapeutics. He holds a B.S. in Business Administration and Finance from Boston University and an MBA in Finance from New York University’s Leonard N. Stern School of Business.

Todd James

Executive Vice President, Chief Financial Officer

Todd R. James serves as Chief Financial Officer of Bambusa Therapeutics, where he leads the company’s finance organization, capital markets strategy, and investor relations.

Prior to joining Bambusa, Mr. James founded TRJ BioAdvisors, where he advised biotechnology CEOs and Boards on capital markets strategy, investor relations, corporate communications, and special situations including mergers and acquisitions, shareholder activism defense, and clinical data disclosures.

Previously, Mr. James served as Senior Vice President of Corporate Affairs and Investor Relations at Viridian Therapeutics. Earlier, he held leadership roles of increasing responsibility at Acceleron Pharma, where he was a member of the Executive Committee and built the company’s investor relations, corporate communications, and broader external stakeholder engagement functions. During his tenure, he supported multiple public equity financings totaling more than $1 billion prior to the company’s $11.5 billion acquisition by Merck.

Earlier in his career, Mr. James served as a Senior Vice President at The Trout Group / Trout Capital and began his career at Thomson Financial providing capital markets intelligence to publicly traded biotechnology companies.

Mr. James has been recognized multiple times by Institutional Investor as a member of the All-America Executive Team for excellence in biotechnology investor relations. He holds a B.A. in Economics with a concentration in Finance from Moravian University.

Jen Salstrom

Vice President, Clinical Development

Bio here.

BBT002

Type 2 (T2) inflammatory diseases are characterized by skewed T2 immune responses driven by T2 cytokines including IL-4, IL-13, and IL-5. In specifics, IL-4 and IL-13, acting through IL-4Rα, promote Th2 polarization, IgE production, barrier dysfunction, mucus hypersecretion, and tissue remodeling, while IL-5 sustains eosinophil maturation, survival, and effector damage. These cytokines drive T2 inflammation across the airways, skin, and gut, contributing to diseases such as chronic obstructive pulmonary disease (COPD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergy, chronic spontaneous urticaria (CSU), and eosinophilic esophagitis (EoE), and making them key therapeutic targets1. Dual targeting IL-4Rα and IL-5 offers advantages over single targeting of IL-4Rα or IL-5 or upstream alarmin proteins (e.g., TSLP, IL-33) by preventing escape (or “leakage”2) of the downstream T2 cytokines (IL-4, IL-13 and IL-5) and providing complete inhibition of the pathogenic inflammation.

BBT002 blocks the entire spectrum of Type 2 cytokines (IL-4, IL-13, and IL-5) while incorporating Fc mutations that eliminate unwanted effector functions and extend half-life for longer dosing intervals. The dual targeting design positions it to provide more comprehensive benefits over current single targeting therapies across T2 inflammatory diseases, particularly those with significant eosinophilic inflammation, while eliminating the risk of eosinophilia associated with anti-IL-4Rα monotherapy.

  1. Nature Reviews Immunology: Allergy and Immunology Study (2025) — https://www.nature.com/articles/s41423-025-01261-2
  2. Wiley Online Library: Allergy Journal Article (2023) — https://onlinelibrary.wiley.com/doi/full/10.1111/all.16537

BBT001

BBT001 is a bispecific IgG1 antibody for Type 2 inflammatory dermatological conditions. Using a 2+2 format, it simultaneously engages IL-4Rα and IL-31 to deliver faster and synergistic efficacy compared to existing treatments.

The drug incorporates Fc modifications that enhance FcRn affinity and extend half-life, enabling longer dosing intervals.

BBT001’s innovation addresses a critical treatment gap. While targeting IL4/13 tackles the fundamental Th2 inflammatory cascade, it does not effectively reduce IL-31 levels, providing only slow, moderate itch relief. This leaves patients trapped in the destructive “itch-scratch cycle” where continuous scratching compromises skin barrier function and perpetuates inflammation.

BBT001’s direct IL-31 targeting is designed to immediately affect sensory nerves, rapidly reducing itchiness while accelerating skin lesion improvement. This dual-pathway approach promises to break the itch-scratch cycle more effectively than single-target therapies, potentially transforming treatment for Type 2 inflammatory dermatological conditions.

Mike Malynn

Director, Finance

Mike Malynn is Director, Finance at Bambusa. Mike brings seven years of finance and operations experience scaling biotech companies and drives Bambusa’s financial strategy to support our mission of delivering transformative treatments. Prior to joining Bambusa, Mike led U.S. operations and supported portfolio companies from inception through seed stage as Finance Manager at Gordian Ventures. He was also the first finance employee at Silicon Therapeutics, where he built the finance function and helped drive the company’s acquisition by Roivant Sciences.

Based in Boston, Massachusetts, Mike holds a B.S.B.A in Business Economics from Suffolk University, graduating Summa Cum Laude.

Shaoyang Yeh, DPhil

Associate Director, CMC

Shaoyang Yeh, DPhil, is Associate Director of CMC at Bambusa Therapeutics. Shaoyang brings extensive process development and CMC experience from leadership roles at MabPlex USA (antibody drug conjugates), Emergent BioSolutions (Phase III vaccines), and BioLegend/Revvity (diagnostic antibodies and reagents). At MabPlex, he worked directly with clients on process design, technology transfer, and regulatory filings for novel biologic products.

Based in San Diego, Shaoyang holds bachelor’s degrees in Bioengineering and Biology from UC San Diego, a master’s in Biomedical Engineering from Cornell, and a DPhil in Engineering Science from Oxford, focusing on tissue engineering and bioprocessing.

Tracy Ji, MD

Director, Clinical Operations

Xiaoping (Tracy) Ji, MD is a Director, Clinical Operations at Bambusa. Leveraging over 19 years of clinical trial experience in her strategic leadership role, she previously served as Project Director at LabCorp, managing global Phase I-III trials across Australia, USA, and EU. Prior to LabCorp, Tracy worked with several global pharmaceutical companies including GSK, Novartis, Roche, and Eisai, gaining extensive knowledge in trial management from both sponsor and CRO perspectives.

 Based in Beijing, China, Tracy holds a Postgraduate Diploma in Public Health from the University of Auckland, New Zealand, complemented by a Bachelor of Clinical Medicine from Heilongjiang University of Chinese Medicine.

Wei Liang, PhD

Director, Development Sciences

Wei Liang, Ph.D., is the Director, Development Sciences at Bambusa and brings over 13 years of post-Ph.D. research and development experience across multiple disease areas to his role. Wei previously served as the Associate Director, R&D at Ansun Biopharma, where he led the cell therapy R&D programs and contributed to the development of a biologic drug candidate. Prior to that, he served as Associate Director I at BioDuro-Sundia, where he rebuilt and led its Oncology San Diego division.

Wei earned his B.S. from the University of Science and Technology of China and completed his Ph.D. at the City of Hope Comprehensive Cancer Center. He continued his research training with postdoctoral work at City of Hope and UC, San Diego.

Lisa Li, MD

Senior Director, Clinical Operations

Lisa Li is a Senior Director, Clinical Operations at Bambusa. Lisa brings extensive clinical operations expertise to her current role, with experience spanning a broad range of therapeutic areas, including infectious disease, dermatology, oncology, pain, rare disease, In addition to operational leadership, Lisa also contributed to corporate strategic initiatives, including supporting the sale of clinical assets during company restructuring at Vital Therapies.

Originally from Beijing, China, Lisa holds a medical degree and earned an MSc in Human Nutrition from the University of Glasgow. She is currently based in San Diego, California.

Jingjing Jiang, MD, PhD

Senior Director, Development Sciences

Dr. Jingjing Jiang is Senior Director of Development Sciences at Bambusa Therapeutics. With expertise in translational research and development sciences, she has a strong track record of building R&D teams, advancing therapeutic platforms, and bridging preclinical and clinical research. Jingjing has held roles at biotech companies of various sizes, including Poseida Therapeutics, contributing to innovative drug development across multiple therapeutic modalities.

Jingjing holds an M.D. from Zhejiang University and a Ph.D. in Biomedical Engineering from UC Irvine.

Melody Zhu, PhD

Vice President, Corporate Development and Strategy

Melody (Yun) Zhu, PhD, is the Vice President, Corporate Development & Strategy at Bambusa Therapeutics. Melody brings extensive cross-functional experience spanning R&D, business strategy, and external innovation across the pharmaceutical and biotech industries. Prior to joining Bambusa, Melody served as Director of External Innovations at BioNTech in Shanghai, where she led the search and evaluation of potential in-licensing opportunities, including assets from Duality and MediLink. Melody also held leadership roles at Sanofi driving portfolio development across Immunology & Inflammation and Oncology, contributing to programs including Dupixent and Itepekimab. She began her career in strategy consulting with Boston Consulting Group (BCG) and IQVIA.

Originally from China, Melody earned her Ph.D. in Biochemistry from The Chinese University of Hong Kong, and her B.S. in Biochemistry from Nanjing University.

Wei Lin, MD ScM

Vice President, Clinical Development

Wei Lin, MD, ScM, is Vice President of Clinical Development at Bambusa. Wei brings extensive experience in clinical development across the I&I therapeutic area. Prior to joining Bambusa, she served as Senior Director and Clinical Lead at Everest Medicines, where she was responsible for the global development of a BTK inhibitor in glomerular diseases. Previously, she was Director and Clinical Lead at Pfizer, overseeing rheumatology and inflammatory bowel disease (IBD) programs. There, she successfully led China’s Phase 3 development of tofacitinib for psoriatic arthritis and ankylosing spondylitis, resulting in NDA approvals. Her team also managed multiple clinical programs in systemic lupus erythematosus, ulcerative colitis, systemic juvenile idiopathic arthritis, and dermatomyositis in China.

Originally from Xiamen, China, Wei earned her MD from Peking University and holds a ScM in Epidemiology from Johns Hopkins University.

Wenbing Hu, PhD

Vice President, Head of CMC

Wenbing Hu, PhD, is Vice President and Head of CMC at Bambusa Therapeutics. Wenbing brings extensive expertise in biologics CMC development and manufacturing, previously serving as Senior Director of Pharmaceutical Development at Ansun Biopharma, where he led CMC activities for late-stage clinical trials. Prior to Ansun, Wenbing held leadership roles at Sorrento Therapeutics, overseeing analytical development, quality control, and formulation, and successfully advanced multiple antibody and mRNA projects through clinical phases. His deep experience spans from early-stage CMC development to global regulatory filings and GMP manufacturing operations.

Based in San Diego, California, Wenbing earned his PhD in Analytical Chemistry from the Institute of Chemistry, Chinese Academy of Sciences.

Crystal MacKay

Chief Operating Officer

Crystal MacKay is the Chief Operating Officer at Bambusa. Crystal brings extensive healthcare experience to her current role, having previously served as a Director of Healthcare Investment Banking at BTIG, where she was responsible for transaction execution in the Life Science & Diagnostic Tools and Medical Technology sectors. Crystal built operational expertise through leadership roles at innovative healthcare companies, including Oxford Immunotec, where she played a key role in strategic initiatives during the company’s transition, Strata Pathology Services, and Calloway Laboratories, where she served on the Board of Directors. 

Based in Boston, Massachusetts, Crystal holds a Bachelor of Arts in Business Communications from the University of Massachusetts and maintains securities licenses including SIE, Series 79, and Series 63.

Thang Ho, PhD

Co-Founder and Chief Development Officer

Thang Ho, Ph.D. is the Co-Founder and Chief Development Officer at Bambusa, where he leads an integrated team spanning preclinical research, translational medicine, toxicology, and clinical pharmacology while playing a critical role in shaping the company’s strategy across U.S. and global programs. Prior to Bambusa, Thang served as Director of Clinical Pharmacology and Pharmacometrics at BioNTech, leading clinical pharmacology strategies for innovative programs including cell and gene therapies and immuno-oncology agents. His career also includes scientific roles at Takeda, CytomX, and Vertex Pharmaceuticals.

Trained as a systems pharmacologist and engineer, Thang holds a Ph.D. in Chemical Engineering from the University of Pittsburgh, and earned his B.S. and M.S. in Chemical Engineering from the University of Arkansas. Originally from Da Nang, Viet Nam, Thang is based in Boston, Massachusetts.

Shanshan Xu, MD, PhD

Founder and Chief Executive Officer

Shanshan Xu, MD, PhD, is the Founder and Chief Executive Officer of Bambusa. Shanshan founded Bambusa with a belief that the I&I field is long overdue for innovative approaches and transformative cutting-edge solutions.

Prior to founding Bambusa, Shanshan served as Head of Global External Innovations at BioNTech, where she and her team sourced and executed 13 strategic partnerships and acquisitions to expand BNT’s pipeline. Her most notable accomplishment was identifying and acquiring Biotheus, which brought BNT327 (now partnered with BMS in a deal valued up to $11.1B). In addition, she identified the I&I molecules within Biotheus that ultimately became the foundation of Bambusa. Her portfolio also included the Duality, MediLink and OncoC4 partnerships, Tier 1 oncology programs. Before joining BioNTech in 2020, Shanshan worked on Wall Street as a Research Analyst.

Originally from Harbin, China, Shanshan spent almost half of her life in Mainland China, where she received her medical degree. She also holds a Ph.D. from UC-Irvine and an MBA from MIT.